AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Companies announce revision of licensing agreement for cancer cell line vaccines.
2004 OCT 6 - (NewsRx.com & NewsRx.net) -- The Immune Response Corporation (IMNR), a biopharmaceutical company, and NovaRx Corporation, a privately held cancer-focused company, have signed a licensing agreement to transfer all of The Immune Response Corporation's in-licensed development and marketing rights of the Sidney Kimmel Cancer Center's (SKCC) patent portfolio for cancer cell line vaccines to NovaRx.
In addition, NovaRx agreed to pay The Immune Response Corporation the total sum of $1,050,000, including an upfront fee and a final payment due on or before August 2007. The Immune Response Corporation had previously licensed the cancer cell vaccine technology from SKCC in 1994.
In 1997, The Immune Response Corporation sublicensed a portion of the SKCC patented technology to NovaRx for their exclusive use in treating a variety of cancers and has received milestone payments related to those licenses. The previously licensed technology specifically covers blocking activity of a potent immune suppressive cytokine, called transforming growth factor-beta (TGFB), which is produced by tumor cells. ...
- The Immune Response Corporation Announces Acquisition Of T Cell Receptor...
- Press release article from: PR Newswire December 13, 1999 700+ words
...PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) today...intellectual property to The Immune Response Corporation, in exchange for cash, stock and royalties. The Immune Response Corporation owns additional TCR...
- Connetics and XOMA Sell T Cell Receptor Technology to the Immune Response...
- Press release article from: Business Wire December 13, 1999 700+ words
...intellectual property to The Immune Response Corporation (IRC, Nasdaq:IMNR...stock and royalties. The Immune Response Corporation owns additional TCR...and common stock of The Immune Response Corporation, as well as royalties...
- THE IMMUNE RESPONSE CORPORATION'S LICENSED B CELL LYMPHOMA TECHNOLOGY RECEIVES...
- Press release article from: PR Newswire April 25, 1996 700+ words
...PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced...exclusively licensed to The Immune Response Corporation. This technology provides...Kimmel Cancer Center. The Immune Response Corporation is a biopharmaceutical...
- THE IMMUNE RESPONSE CORPORATION'S LICENSED TECHNOLOGY SHOWN TO ERADICATE BRAIN...
- Press release article from: PR Newswire April 2, 1996 700+ words
...PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) today...collaborative effort between The Immune Response Corporation and SKCC has already...Executive Officer of The Immune Response Corporation. "We believe this technology...
- THE IMMUNE RESPONSE CORPORATION COMPLETES ENROLLMENT OF PHASE II CLINICAL TRIAL...
- Press release article from: PR Newswire March 12, 1996 700+ words
...PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced...executive officer of The Immune Response Corporation. "We are excited about...debilitating disease." The Immune Response Corporation is a biopharmaceutical...
- THE IMMUNE RESPONSE CORPORATION'S LICENSED TECHNOLOGY RECEIVES U.S. PATENT
- Press release article from: PR Newswire March 14, 1996 700+ words
...PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced...exclusively licensed to The Immune Response Corporation. This newly patented...therapy programs. The Immune Response Corporation is a biopharmaceutical...
- The Immune Response Corporation Postpones Follow-on Public Offering of Common...
- Press release article from: PR Newswire August 7, 1996 700+ words
...PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced...executive officer of The Immune Response Corporation. "Immune Response has...less volatile." The Immune Response Corporation is a biopharmaceutical...
- The Immune Response Corporation and NovaRx Corporation Announce Revision of...
- Press release article from: PR Newswire September 8, 2004 700+ words
The Immune Response Corporation , a biopharmaceutical company...agreement to transfer all of The Immune Response Corporation's in-licensed development...NovaRx agreed to pay The Immune Response Corporation the total sum of $1,050...